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ABSTRACT:   
OBJECTIVES: To assess bone density testing (BDT) use among prostate cancer 
survivors receiving ADT, and downstream implications for osteoporosis and fracture 
diagnoses as well as pharmacologic osteoporosis treatment in a national integrated 
delivery system.  
METHODS: We identified 17,017 men with prostate cancer who received any ADT 
between 2005 and 2014 using Veterans Health Administration cancer registry and 
administrative data. We identified claims for BDT within a 3-year period of ADT 
initiation. We then used multivariable regression to examine the association between 
BDT use and incident osteoporosis, fracture, and use of pharmacologic treatment.  
RESULTS: We found a minority of patients received BDT (n=2,502, 15%), however the 
rate of testing increased to over 20% by the end of the study period. Men receiving BDT 
were older at diagnosis and had higher-risk prostate cancer (both p<0.001). 
Osteoporosis and fracture diagnoses, use of vitamin D ± calcium, and bisphosphonates 
were all more common in men who received BDT. After adjustment, BDT, and to a 
lesser degree, 2 or more years of ADT, were both independently associated with 
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CONCLUSIONS: Bone density testing is rare among prostate cancer patients treated 
with ADT in this integrated delivery system. However, BDT was associated with 
substantially increased treatment of osteoporosis indicating an underappreciated 
burden of osteoporosis among prostate cancer survivors initiating ADT. Optimizing BDT 
use and osteoporosis management in this at-risk population appears warranted.  
 
INTRODUCTION 
Prostate cancer is a common malignancy in American men, many of whom 
eventually undergo androgen deprivation therapy (ADT) as part of their prostate cancer 
management.1,2 While ADT may be warranted to treat high-risk and advanced disease, 
it is associated with significant, often under-appreciated, adverse effects related to 
hypogonadism, including metabolic syndrome, cardiovascular disease, and decreased 
bone health.3 
The effects of ADT on bone manifest as significantly decreased bone mineral 
density, and consequently increased fracture risk.4-8 Guidelines and existing literature 
recommend screening for osteoporosis at the time of ADT initiation to facilitate risk 
stratification and early pharmacological intervention where appropriate.9-13 The National 
Comprehensive Cancer Network’s Task Force Report: Bone Health in Cancer Care 
states that “in patients who will be undergoing therapy that lowers sex steroids, the 
NCCN Guidelines for Breast and Prostate Cancers recommend evaluation with baseline 
and periodic follow-up DXA scans to evaluate bone health and risk of fracture.” 14 
However, existing data demonstrate bone density testing (BDT) rates remain below 
optimal levels.15-20 Bone health assessment is especially warranted in patients with 
other risk factors for skeletal-related events such as smoking, alcohol use, and low 
vitamin D levels.21 These risk factors disproportionately afflict US veterans, who 
subsequently have higher rates of mortality following fractures, further magnifying the 
need for BDT.22 In spite of these increased risks, the national patterns of BDT use and 
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In this context, we characterized BDT use and outcomes in a national integrated 
delivery system cohort of veteran prostate cancer patients treated with ADT. We 
evaluated BDT rates at the initiation of ADT, and assessed downstream skeletal-related 
outcomes including osteoporosis, fracture, and pharmacologic treatment for 
osteoporosis. Better understanding bone health practice patterns and outcomes through 
this study will define the burden of bone disease among high-risk prostate cancer 
patients and opportunities to improve the quality of their care. 
 
MATERIALS AND METHODS 
Study population 
We used the Veterans Administration (VA) Central Cancer Registry to identify 
patients with an incident diagnosis of pathologically-confirmed prostate cancer between 
2005 and 2008 who were treated with ADT, defined as surgical orchiectomy or medical 
castration with an injectable gonadotropin releasing hormone agonist, using inpatient 
and outpatient pharmacy and utilization coding.16 More than 99% of the men in this 
cohort received medical castration, among whom 93% received goserelin, 4% 
leuprolide, and 3% another agent. We excluded patients with other cancer diagnoses, 
death within 30 days of diagnosis, or diagnosis at autopsy. We linked these data with 
VA administrative files containing inpatient, outpatient, laboratory, radiology, pharmacy, 
and facility data with follow up through the year 2014. This allowed us to examine ADT 




Our primary outcome was receipt of BDT at the patient level, consisting of either 
dual x-ray absorptiometry or quantitative computed tomography. We assessed BDT by 
identifying claims submitted within 18 months prior to or following initiation of ADT, 
which should capture both recommended testing prior to ADT initiation as well as any 
delayed or follow up monitoring. We utilized a larger time window than previous studies 
in order to maximize our capture of BDT performed surrounding ADT. As such our BDT 
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secondary outcomes were downstream bone health measures, including any 
administrative codes suggesting a new diagnosis of osteoporosis or any fracture 
following ADT initiation. We also queried pharmacy claims for any new prescriptions 
suggesting osteoporosis treatment after induction of ADT. Specifically, we assessed for 
dispensing of vitamin D ± calcium (calcium carbonate, calcium citrate, calcium acetate, 
calcium) as recommended for all patients initiating ADT, bisphosphonates (alendronate, 
pamidronate, risedronate, zoledronic acid, ibandronate), or denosumab, a bone health 
treatment for metastatic prostate cancer which has also been demonstrated to increase 
BMD and lower fracture rates in men receiving ADT.23  
 
Statistical analysis 
We used descriptive statistics to assess differences in demographics, disease, 
and treatment characteristics between prostate cancer patients treated with ADT who 
received BDT and those who did not. We examined covariates including age, race, 
ethnicity, marital status, employment status, Gleason score, D’Amico prostate cancer 
risk group, primary prostate cancer treatment, and Charlson comorbidity score 
(calculated using healthcare claims for the 12 months prior to prostate cancer 
diagnosis).24,25 We used student’s t-tests and chi-square testing as appropriate.  
To assess the independent association of BDT use with our secondary outcomes 
of incident osteoporosis, fracture, and osteoporosis treatment, we fit separate multiple 
logistic regression models for each outcome with the primary exposure of BDT. Given 
its particularly detrimental impact on bone health, we adjusted these models using an 
indicator variable for ≥2 years of ADT,4-8 as well as the following covariates: age, race, 
ethnicity, marital status, D’Amico risk score, prostate cancer treatment type, and 
Charlson comorbidity score.  
All analyses were conducted using SAS software (SAS Institute, Cary, NC) and 
all testing was two-sided using an alpha of 0.05. This study was approved by the VA 
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Among the 17,017 prostate cancer patients receiving ADT, a minority received 
BDT during the study period (2,502, 15%). As shown in Table 1, men receiving BDT 
were older and diagnosed with higher risk disease (p <0.001 for both). Among patients 
who received BDT there were slightly lower rates of initial treatment with combination 
radiation therapy and ADT (p <0.001). Testing rates increased consistently over the 
years of the study period, as illustrated in Figure 1.  
Bone health outcomes among men with prostate cancer treated with ADT who 
did and did not receive BDT are shown in Table 2. Recipients of BDT were significantly 
more likely to be diagnosed with osteoporosis and fracture and more likely to receive 
treatment for osteoporosis (p <0.001 for all). As illustrated in Figure 2, differences in 
bone health outcomes among patients following the receipt of BDT were dramatic. For 
example, after BDT, diagnoses of osteoporosis and fracture increased nearly 10- and 3-
fold respectively. In addition, rates of vitamin D use more than doubled after BDT, while 
bisphosphonate use also increased approximately 10-fold. Denosumab was rare but its 
use also increased. 
As shown in Table 3, after adjustment for patient and disease characteristics, 
BDT remained associated with the diagnosis (adjusted odds ratio (aOR) 6.21, 95% CI 
5.40 – 7.15) and treatment of osteoporosis (aOR 6.47, 95% CI 5.66 – 7.39), as well as 
slightly increased odds of fracture diagnosis (aOR 1.29, 95% CI 1.08 – 1.53). Similarly, 
though to a lesser degree, the receipt of 2 or more years of ADT was significantly 
associated with diagnosis (aOR 1.47, 95% CI 1.28 – 1.69) and treatment of 
osteoporosis (aOR 1.86, 95% CI 1.71 – 2.03), in addition to incident fracture diagnosis 
(aOR 1.21, 95% CI 1.06 – 1.40). 
 
DISCUSSION 
We found that roughly 1 in 7 patients with prostate cancer receiving ADT 
underwent BDT within the 3 years surrounding initiation of castration in this national 
integrated delivery system. However, by the end of the study period in 2014 this number 
had increased to more than one in five. Bone density testing was associated with 
dramatic increases in the diagnosis and treatment of osteoporosis, suggesting a non-
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regarding which patients would benefit most from testing may lead to selection bias, it is 
unlikely that the nearly 90% of untested men in our cohort were at uniformly low-risk of 
osteoporosis and fracture. Even after controlling for patient and disease characteristics, 
both BDT and, to a lesser degree, an extended duration of ADT were independent 
predictors of osteoporosis and fracture diagnoses. These findings confirm efforts are 
necessary to encourage bone health testing and osteoporosis treatment in this high-risk 
population of prostate cancer survivors to decrease avoidable harms of castration with 
ADT. 
Our findings are consistent with prior data showing low rates of BDT in patients 
receiving ADT. Within veterans specifically, our finding of a 13% BDT rate is congruent 
with previously published rates of approximately 13% a decade ago, indicating a 
persistent quality gap.19,20 Though the uptrend in testing rates observed in this study is 
encouraging, 20% of patients undergoing BDT is still well below an ideal testing rate. 
While prior studies in veterans were limited to smaller geographical areas capturing 
several hundred patients, our national cohort is much larger, representing veterans 
across the United States, and reflects more contemporary practice patterns. Indeed, 
data from large studies in Medicare populations have also found persistently low rates 
varying from 6% to 14.5%, albeit with trends towards increasing utilization over time, 
signaling systematic poor compliance with recommended care.16-18 Recent results from 
other clinical contexts also underscore that the problem of low rates of BDT use among 
patients at high risk for bone-related complications extends beyond the realm of 
prostate cancer into breast cancer.26 
The osteoporosis and fracture diagnoses identified in this study underscore the 
importance of appropriate bone health testing among high-risk prostate cancer 
survivors. The striking 5-fold difference in osteoporosis diagnosis between those who 
did and did not receive BDT suggests a significant amount of underlying disease in the 
87% of men who were not tested. Moreover, the 10-fold increase in osteoporosis 
diagnosis following BDT, and 2- to 3-fold higher rates of osteoporosis treatment in the 
tested group compared to untested men demonstrate that testing yields actionable 
information for clinicians, who can intervene to potentially help avoid downstream bone 
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diagnoses were more modest, presumably discovered incidentally during evaluation for 
osteoporosis, this is a morbid complication highlighting that improvements in 
identification and treatment of skeletal fractures may be warranted. 
In combination with the existing literature, our findings support efforts to increase 
rates of appropriate BDT in men undergoing ADT, and suggest that such testing could 
in turn yield improved diagnosis and treatment of ADT’s adverse effects on the skeletal 
system. However, exploring the behaviors and norms of physicians and patients which 
contribute to persistently poor compliance with guideline-recommended bone health 
assessment among men on ADT is critical and should help inform subsequent 
intervention design. At least four addressable reasons may be driving our observations. 
First, providers may be unaware of the guideline recommendations to screen men 
receiving ADT for osteoporosis issued by groups such as the National Comprehensive 
Cancer Network, though the negative impacts of ADT on bone health have long been 
established.14,27 Second, many clinicians may not feel comfortable utilizing instruments 
such as the fracture risk assessment model (FRAX) tool, which combines BDT results 
with clinical risk factors to guide treatment (though it can be calculated without BMD).28 
Third, there may be fragmentation among providers caring for these patients. While 
specialists order and manage ADT, in the absence of metastatic disease it is often 
primary care clinicians who are tasked with the diagnosis and treatment of osteoporosis 
in men with prostate cancer. Last, the evidence supporting the impact of vitamin D, 
calcium, and bisphosphonates on decreasing clinically-relevant fractures is mixed, 
generating confusion about the efficacy of these interventions and decreasing the 
likelihood of their utilization.29,30 However, current recommended care includes placing 
men older than 50 on vitamin D and calcium supplementation, a target not achieved in 
the majority of this cohort.31 It is possible some men in this study may have obtained 
these supplements over the counter, but this is unlikely given VA pharmacy coverage 
and cost differences. Future work must better clarify the impacts of BDT and 
pharmacologic intervention on subsequent fracture rates. Taken together, these findings 
suggest further study is needed to address this gap in high-risk prostate cancer care 
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There are several limitations to this study. First, our results may not be 
generalizable to all prostate cancer patients treated with ADT, as additional risks and 
unmeasured differences may be present among veterans. However, our findings are 
consistent with results from other non-VA datasets, and the issues of low rates of BDT 
and low rates of subsequent treatment are not unique to this population. Further, our 
nationally-representative cohort and the lack of age exclusions as in Medicare studies 
increases generalizability. Second, although our study includes patients with follow up 
through 2014, the nine-year span of our cohort from incident cancer diagnosis to last 
follow up may suggest that our observed BDT rate could be an underestimate of current 
rates. However, the consistency of findings across studies and negligible increases 
indicate a persistent gap in care. Third, these retrospective data do not include the 
actual indications for BDT (other than initiating ADT) and therapeutic interventions, only 
whether or not they were received. Nonetheless, our use of incident diagnosis and 
pharmacy codes, coupled with our study design, support our conclusions of significantly 
underappreciated bone disease burden among these patients regardless of testing 
indication. It is possible that our analysis may be an underestimate of the rates at which 
physicians are assessing osteoporotic fracture risk in these men since we do not 
capture assessment methods that do not include BMD. However, given that BMD 
testing is the gold standard method and is the approach recommended by the NCCN 
we believe that these methods likely capture most of the bone health assessments 
being performed in this population. It is also important to note that BDT is not causally 
associated with osteoporosis or fracture. Rather, the use of BDT allows for the 
identification of potentially subclinical bone disease, which can subsequently lead to 
earlier intervention and long-term reduction of harm. Lastly, our analysis is subject to 
the inherent limitations of observational research and while we have attempted to 
control for confounding with multiple regression techniques, we were not able to fully 
account for unobserved confounders. 
These limitations notwithstanding, our results have important implications for 
men receiving ADT and those involved their care. First, urologists must be vigilant to 
minimize the burdens related to the adverse effects of ADT on bone health. In spite of 
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rates of appropriate testing remain well below optimal levels. Second, from the 
standpoint of payers and policymakers, the costs of ADT-related adverse effects are 
significant, and interventions focused on mitigating the skeletal impacts of ADT have 
been found to be cost-effective.32 Increased attention should be directed towards 
encouraging the use of BDT in these patients. Last, the effects of ADT, osteoporosis, 
and fractures have significant negative implications for quality of life and survival. 
Increased use of appropriate BDT can potentially facilitate improved patient wellbeing 
and outcomes. 
There appears to be significant under-diagnosis and treatment of osteoporosis 
among men with prostate cancer receiving ADT. Our findings suggest substantial 
opportunities exist to reduce bone-related complications by improving use of BDT at 
ADT initiation to allow for early intervention. Better understanding how providers care for 
these patients who are at high risk for bone-related complications, and how to most 
effectively target interventions to increase bone health assessment is justified. In 
addition, quantifying the degree to which improved detection and treatment of 
osteoporosis can help to lower clinically-relevant fracture rates in this high-risk 
population may help foster guideline concordant care. Efforts to optimize BDT among 
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Table 1. Characteristics of patients on androgen deprivation therapy according to bone 
density testing. 







Mean Age at Diagnosis, y (Std. Dev.) 68.6 (9.1) 70.1 (9.3) <0.001 
Race, %   0.05 
   White 67 66  
   Black 29 31  
   Other/Unknown 4 3  
Ethnicity, %   <0.001 
   Hispanic 5 10  
   Non-Hispanic 94 89  
   Unknown 1 1  
Marital Status, %   0.30 
   Married 49 49  
   Divorced/Separated 29 27  
   Single/Never Married 8 9  
   Widowed 13 15  
   Unknown <1 <1  
Status, %   0.07 
   Alive 74 72  
   Dead 26 28  
Employment Status, %   0.50 
   Full-Time 7 6  
   Part Time  3 3  
   Retired 53 54  
   Self-Employed 2 2  
   Unemployed 34 34  
   Active Military <1 <1  
   Unknown 1 <1  
Gleason Score, %   <0.001 
   6 25 21  
   7 42 38  
   8-10 33 41  
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    Low 14 11  
    Intermediate 32 27  
    High 54 63  
Initial Treatment, %   <0.001 
   Observation 6 6  
   ADT Monotherapy 36 38  
   Surgery 8 10  
   Radiation 5 6  
   Surgery + Radiation 1 <1  
   Radiation + ADT 35 28  
   Other <1 1  
   Unknown 8 9  
Comorbidity (Charlson Index), %   0.22 
   0 42 40  
   1 27 27  
   2+ 31 33  
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Table 2. Osteoporosis, fracture, and pharmacologic osteoporosis treatment among 
prostate cancer survivors on ADT according to bone density testing. 
 







Osteoporosis diagnosis 752 (5%) 669 (27%) <0.001 
Fracture diagnosis 1132 (8%) 270 (11%) <0.001 
Osteoporosis treatment    
     Vitamin D * ± Calcium ** 5067 (35%) 1848 (74%) <0.001 
     Bisphosphonate *** 1983 (14%) 1033 (41%) <0.001 
     Denosumab 31 (0.2%) 14 (0.6%) <0.001 
 
*(vitamin D, ergocalciferol, cholecalciferol, 1,25 dihydroxycholecalciferol) 
**(calcium carbonate, calcium citrate, calcium acetate, calcium) 
















This article is protected by copyright. All rights reserved 
Table 3. Multivariable regression results for bone density testing and 2 or more years of 
ADT after adjustment for patient and disease characteristics. 
 
Outcome Bone density testing 
Adjusted Odds Ratio 
(95% CI) * 
2+ Years ADT  
Adjusted Odds Ratio 
(95% CI) * 
Osteoporosis Diagnosis 6.21 (5.40 – 7.15) 1.47 (1.28 – 1.69) 
Osteoporosis Treatment 6.47 (5.66 – 7.39) 1.86 (1.71 – 2.03) 
Fracture Diagnosis 1.29 (1.08 – 1.53) 1.21 (1.06 – 1.40) 
 
* Adjusted for age, race, ethnicity, marital status, D’Amico risk score, prostate cancer 















Figure 1. Rate of bone density testing across years of the study period, with the number 
of men initiating ADT each year represented by the size of the circle. Year 2014 is not 




















Figure 2. Comparison of bone health related diagnoses and treatments among men 
with prostate cancer receiving ADT before and after undergoing bone density testing. 
Among prostate cancer patients initiating ADT, BDT was associated with dramatic 
increases in the diagnosis of osteoporosis and fracture. In addition, bisphosphonate use 




** p value not obtainable as no patients were taking denosumab prior to receiving BDT 
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